KDR and renal cell adenocarcinoma: Clinical trials of peptide-based vaccine therapy using VEGFR-derived epitopes have previously been conducted to assess safety, tolerability, and potential clinical activity in patients with advanced pancreas, gastrointestinal, and renal cell cancers (see Supplementary Table 3)21–28.